K-STREET TRACKER
FOLLOW THE MONEY INTO THE SWAMP
Every federal lobbying filing tagged with a public-company ticker — who is spending, which firms they hire, and which members trade right around the filing.
Filings tracked
19,882
thru 2026-05-08
Total reported $
$2.7B
disclosed lobbying
Distinct clients
2,220
paying companies
Tickers targeted
1,207
public companies
💸 Top Spending Clients
| # | Client | Filings | Total $ |
|---|---|---|---|
| 1 |  PFIZER INC.PFE | 47 | $46.8M |
| 2 |  GENERAL MOTORS COMPANYGM | 61 | $46.8M |
| 3 |  META PLATFORMS INC. AND VARIOUS SUBSIDIARIESMETA | 12 | $44.9M |
| 4 | VISA INC.V | 45 | $37.7M |
| 5 |  AMAZON.COM SERVICES LLCAMZN | 36 | $32.8M |
| 6 |  LOCKHEED MARTIN CORPORATIONLMT | 73 | $29.0M |
| 7 |  FEDEX CORPORATIONFDX | 69 | $27.8M |
| 8 |  ELI LILLY AND COMPANYLLY | 56 | $27.1M |
| 9 |  ALTRIA CLIENT SERVICES LLCMO | 142 | $25.2M |
| 10 |  AMGEN INCAMGN | 19 | $24.9M |
| 11 |  COMCAST CORPORATIONCMCSV | 179 | $24.7M |
| 12 |  MERCK & CO INCMRK | 14 | $24.0M |
| 13 |  SOUTHERN COMPANYSO | 53 | $23.9M |
| 14 |  GOOGLE CLIENT SERVICES LLCGOOGL | 79 | $22.6M |
| 15 |  APPLE INCAAPL | 9 | $22.1M |
| 16 |  T-MOBILE USA INC.TMUS | 121 | $21.0M |
| 17 |  UNITEDHEALTH GROUP INCUNH | 19 | $20.4M |
| 18 |  VERIZON COMMUNICATIONS INC AND VARIOUS SUBSIDIARIESVZ | 40 | $20.1M |
| 19 |  OCCIDENTAL PETROLEUM CORPORATIONOXY | 30 | $19.7M |
| 20 |  MICROSOFT CORPORATIONMSFT | 103 | $18.8M |
| 21 |  QUALCOMM INCORPORATEDQCOM | 40 | $17.2M |
| 22 |  GENERAL DYNAMICS CORPGD | 11 | $17.0M |
| 23 |  BOEING COMPANYBA | 23 | $16.9M |
| 24 | THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)CI | 13 | $16.9M |
| 25 |  ORACLE CORPORATIONORCL | 58 | $16.7M |
🎯 Top Lobbied Tickers
| # | Ticker | Filings | Total $ |
|---|---|---|---|
| 1 | META Meta Platforms Inc. | 129 | $50.2M |
| 2 | PFE Pfizer Inc. | 87 | $48.6M |
| 3 | GM General Motors Company | 103 | $48.4M |
| 4 | V Visa Inc. | 46 | $37.7M |
| 5 | AMZN Amazon.com Inc. | 80 | $35.3M |
| 6 | LMT Lockheed Martin Corporation | 88 | $29.4M |
| 7 | FDX FedEx Corporation | 82 | $28.3M |
| 8 | LLY Eli Lilly and Company | 83 | $28.1M |
| 9 | AMGN Amgen Inc. | 95 | $28.0M |
| 10 | MRK Merck & Co. Inc. | 92 | $27.5M |
| 11 | AAPL Apple Inc. | 64 | $26.8M |
| 12 | GOOGL Alphabet Inc. Class A | 123 | $26.6M |
| 13 | MO | 164 | $26.2M |
| 14 | SO Southern Company | 108 | $26.1M |
| 15 | UNH UnitedHealth Group Inc. | 67 | $23.9M |
| 16 | VZ Verizon Communications Inc. | 116 | $23.8M |
| 17 | TMUS | 159 | $22.7M |
| 18 |  CHTR | 137 | $22.6M |
| 19 | GD General Dynamics Corporation | 127 | $22.5M |
| 20 |  TAT&T Inc. | 134 | $21.6M |
| 21 | ORCL Oracle Corporation | 132 | $20.6M |
| 22 | CMCSA Comcast Corporation | 141 | $20.4M |
| 23 | CI The Cigna Group | 64 | $19.9M |
| 24 | OXY Occidental Petroleum Corporation | 36 | $19.9M |
| 25 | MSFT Microsoft Corporation | 122 | $19.2M |
🆕 Filtered Filings · BSX
clear filters| Date | Ticker | Client | Registrant | Amount | Issue |
|---|---|---|---|---|---|
| 2026-04-20 | BSX | BOSTON SCIENTIFIC CORPORATION | BOSTON SCIENTIFIC CORPORATION | $642K | Medical device procurement and supply chain resiliency. Ensuring VHA patient access to Med Tech as VHA manages supply chain and upgrades its medical surgery and prosthetics procurement contracting. Pain management - working to increase veteran access to multidisciplinary and multimodal pain management to provide for effective non-opioid treatment alternatives. VA Authorization Bill of 2025- Specifically, H.R. 6549 The VA Contracting and Procurement Act. This bill would reform VAs contracting process by modernizing medical implant acquisition and consolidating billing for surgical procedures to enhance delivery of care to veterans. FY2027 Appropriations: Advocacy efforts on including report language in Labor-HHS to advance non-opioid, evidence-based pain management and in VA/DoD accounts to support modernization of procurement processes, including a transparent product add cycle and a streamlined single purchase order mechanism. OECD 2 Pillar Framework Implementation - International t |
| 2026-04-20 | BSX | BOSTON SCIENTIFIC CORPORATION | ALSTON & BIRD LLP | $80K | Issues concerning Medicare reimbursement, AI and medical technology. Advocacy concerning tax issues. Advocacy concerning trade issues. |
| 2026-04-20 | BSX | BOSTON SCIENTIFIC | HOLLIER & ASSOCIATES | $60K | Interntational tax reform, TCJA reauthorization |
| 2026-04-17 | BSX | BOSTON SCIENTIFIC (OFFICE-BASED FACILITY ASSN OBFA) (FKA USPA) | LIBERTY PARTNERS GROUP, LLC | $0 | Medicare Physician Fee Schedule; Medicare Physician Fee Schedule reform; H.R.10136 - Promoting Fairness for Medicare Providers Act of 2024. |
| 2026-04-15 | BSX | BOSTON SCIENTIFIC CORPORATION | BRICK STREET STRATEGY | $20K | Medical Supply Chain program reforms HR 6549, VA Contracting and Procurement Act |
| 2026-01-21 | BSX | BOSTON SCIENTIFIC | HOLLIER & ASSOCIATES | $60K | Interntational tax reform, TCJA reauthorization |
| 2026-01-20 | BSX | BOSTON SCIENTIFIC CORPORATION | ALSTON & BIRD LLP | $80K | Issues concerning Medicare reimbursement, AI and medical technology. Advocacy concerning tax issues. Advocacy concerning trade issues. |
| 2026-01-20 | BSX | BOSTON SCIENTIFIC (OFFICE-BASED FACILITY ASSN OBFA) (FKA USPA) | LIBERTY PARTNERS GROUP, LLC | $0 | Medicare Physician Fee Schedule; Medicare Physician Fee Schedule reform; H.R.10136 - Promoting Fairness for Medicare Providers Act of 2024. |
| 2026-01-16 | BSX | BOSTON SCIENTIFIC CORPORATION | BOSTON SCIENTIFIC CORPORATION | $570K | Ensuring Patient Access to Critical Breakthrough Products Act of 2025(H.R. 5343 and S.1717) - Legislation to create automatic CMS coverage for devices approved via FDA's breakthrough pathway. (CMS rulemaking for Transitional Coverage of Emerging Technologies (TCET) - advocacy for a new, voluntary Transitional Coverage of Emerging Technologies (TCET) pathway that provides national Medicare coverage for Breakthrough-designated technologies, beginning on the date of FDA market authorization.) The Patient Access to Innovative New Technologies Act (PAINT Act) -- proposed legislation that aims to expand access to new medical technologies by improving the Medicare New Technology Add-on Payment (NTAP) program. It would create a single deadline for products in an alternative pathway, ensure breakthrough devices are eligible for conditional approval under NTAP, and prevent disruption in Medicare beneficiaries' access to new treatments. 2025 Reauthorization of the SUPPORT for Patients and Communi |
| 2026-01-12 | BSX | HOLLIER & ASSOCIATES ON BEHALF OF BOSTON SCIENTIFIC | QUICKEL CONSULTING SERVICES, LLC | $12K | Reauthorization of TCJA; International tax proposals |
| 2026-01-05 | BSX | BOSTON SCIENTIFIC CORPORATION | BRICK STREET STRATEGY | $20K | Medical Supply Chain program reforms HR 6549, VA Contracting and Procurement Act |
| 2025-11-06 | BSX | BOSTON SCIENTIFIC | HOLLIER & ASSOCIATES | $60K | Interntational tax reform, TCJA reauthorization |
| 2025-10-20 | BSX | BOSTON SCIENTIFIC CORPORATION | ALSTON & BIRD LLP | $80K | Issues concerning Medicare reimbursement, AI and medical technology. Advocacy concerning tax issues. Advocacy concerning trade issues. |
| 2025-10-20 | BSX | BOSTON SCIENTIFIC (OFFICE-BASED FACILITY ASSN OBFA) (FKA USPA) | LIBERTY PARTNERS GROUP, LLC | $0 | Medicare Physician Fee Schedule; Medicare Physician Fee Schedule reform; H.R.10136 - Promoting Fairness for Medicare Providers Act of 2024; H.R.1 - One Big Beautiful Bill Act. |
| 2025-10-17 | BSX | BOSTON SCIENTIFIC CORPORATION | BOSTON SCIENTIFIC CORPORATION | $570K | Supply Chain - advocacy efforts on topics that could potentially impact the medical device supply chain such as decisions made by the United States House Select Committee on Strategic Competition between the United States and the Chinese Communist Party, outbound investments, raw materials, components, export controls, and shortage/supply chain resiliency reporting regulations. EPA Rulemaking Restricting Ethylene Oxide (ETO) - Proposed rulemaking to place more-stringent limits on emissions and institute new monitoring requirements for ethylene oxide (ETO). Advocacy efforts include educating lawmakers on the importance of ETO in the sterilization of medical devices and potential shortages of sterile medical devices if EPA's proposed changes are enacted. FY2026 National Defense Authorization Act (NDAA) (H.R. 3838/S.2296) - Section 863 of H.R. 3838: Requirement for Contractors to Provide Reasonable Access to Repair Materials If enacted this legislation would enforce an expansive right |
| 2025-10-14 | BSX | HOLLIER & ASSOCIATES ON BEHALF OF BOSTON SCIENTIFIC | QUICKEL CONSULTING SERVICES, LLC | $12K | Reauthorization of TCJA; International tax proposals |
| 2025-10-02 | BSX | BOSTON SCIENTIFIC CORPORATION | BRICK STREET STRATEGY | $20K | Medical Supply Chain program reforms |
| 2025-08-05 | BSX | BOSTON SCIENTIFIC CORPORATION | BRICK STREET STRATEGY | $20K | Medical Supply Chain program reforms |
| 2025-07-21 | BSX | BOSTON SCIENTIFIC CORPORATION | ALSTON & BIRD LLP | $80K | Issues concerning Medicare reimbursement, AI and medical technology. Advocacy concerning tax issues. Advocacy concerning trade issues. |
| 2025-07-21 | BSX | BOSTON SCIENTIFIC | HOLLIER & ASSOCIATES | $60K | Interntational tax reform, TCJA reauthorization |
| 2025-07-21 | BSX | BOSTON SCIENTIFIC (OFFICE-BASED FACILITY ASSN OBFA) (FKA USPA) | LIBERTY PARTNERS GROUP, LLC | $0 | Medicare Physician Fee Schedule; Medicare Physician Fee Schedule reform; H.R.10136 - Promoting Fairness for Medicare Providers Act of 2024; H.R.1 - One Big Beautiful Bill Act. |
| 2025-07-17 | BSX | BOSTON SCIENTIFIC CORPORATION | BOSTON SCIENTIFIC CORPORATION | $570K | Ensuring Patient Access to Critical Breakthrough Products Act of 2023(H.R. 1691) - Legislation to create automatic CMS coverage for devices approved via FDA's breakthrough pathway. 2025 Reauthorization of the SUPPORT for Patients and Communities Act (Public Law 115-271)- Advocacy for reauthorization of the SUPPORT Act, specifically for FDA approved alternative treatments for Chronic Pain, and medical devices role to address the opioid epidemic. CMS rulemaking for Transitional Coverage of Emerging Technologies (TCET) - advocacy for a new, voluntary Transitional Coverage of Emerging Technologies (TCET) pathway that provides national Medicare coverage for Breakthrough-designated technologies, beginning on the date of FDA market authorization. Implementation of the Food and Drug Omnibus Reform Act of 2022 (Public Law 117-328) - advocacy efforts on Medical Device User Fee Amendments (MDUFA) reauthorization, riders, and device shortages. Implementation of the Chips and Science Act (Public La |
| 2025-07-16 | BSX | HOLLIER & ASSOCIATES ON BEHALF OF BOSTON SCIENTIFIC | QUICKEL CONSULTING SERVICES, LLC | $12K | Reauthorization of TCJA; International tax proposals |
| 2025-04-21 | BSX | BOSTON SCIENTIFIC CORPORATION | ALSTON & BIRD LLP | $80K | Issues concerning Medicare reimbursement. Advocacy concerning tax issues. Advocacy concerning trade issues. |
| 2025-04-21 | BSX | BOSTON SCIENTIFIC | HOLLIER & ASSOCIATES | $60K | Interntational tax reform, TCJA reauthorization |
| 2025-04-21 | BSX | BOSTON SCIENTIFIC (OFFICE-BASED FACILITY ASSN OBFA) (FKA USPA) | LIBERTY PARTNERS GROUP, LLC | $0 | Medicare Physician Fee Schedule; Medicare Physician Fee Schedule reform; H.R.10136 - Promoting Fairness for Medicare Providers Act of 2024. |
| 2025-04-17 | BSX | BOSTON SCIENTIFIC CORPORATION | BOSTON SCIENTIFIC CORPORATION | $400K | Ensuring Patient Access to Critical Breakthrough Products Act of 2023(H.R. 1691) - Legislation to create automatic CMS coverage for devices approved via FDA's breakthrough pathway. 2025 Reauthorization of the SUPPORT for Patients and Communities Act (Public Law 115-271)- Advocacy for reauthorization of the SUPPORT Act, specifically for FDA approved alternative treatments for Chronic Pain, and medical devices role to address the opioid epidemic. CMS rulemaking for Transitional Coverage of Emerging Technologies (TCET) - advocacy for a new, voluntary Transitional Coverage of Emerging Technologies (TCET) pathway that provides national Medicare coverage for Breakthrough-designated technologies, beginning on the date of FDA market authorization. Implementation of the Food and Drug Omnibus Reform Act of 2022 (Public Law 117-328) - advocacy efforts on Medical Device User Fee Amendments (MDUFA) reauthorization, riders, and device shortages. Implementation of the Chips and Science Act (Public La |
| 2025-04-16 | BSX | HOLLIER & ASSOCIATES ON BEHALF OF BOSTON SCIENTIFIC | QUICKEL CONSULTING SERVICES, LLC | $12K | Reauthorization of TCJA; International tax proposals |
| 2025-04-09 | BSX | BOSTON SCIENTIFIC CORPORATION | BRICK STREET STRATEGY | $20K | Medical Supply Chain program reforms |
| 2025-02-03 | BSX | BOSTON SCIENTIFIC CORPORATION | ALSTON & BIRD LLP | $0 | Issues concerning health care reimbursement, tax, trade. Issues concerning health care reimbursement, tax, trade. Issues concerning health care reimbursement, tax, trade. |
| 2025-01-21 | BSX | BOSTON SCIENTIFIC CORPORATION | ALPINE GROUP PARTNERS, LLC. | $50K | Issues related to treatment of chronic pain Reauthorization of the Pandemic All Hazards Preparedness Act, issues related to supply chains for medical devices H.R. 4531 SUPPORT Act Reauthorization S.2922 Advancing Research for Chronic Pain Act of 2023 New Tech Add On Payment S. 866, the American Innovation and Jobs Act H.R. 7024, the Tax Relief for American Families and Workers Act of 2024 |
| 2025-01-21 | BSX | BOSTON SCIENTIFIC CORPORATION | BRICK STREET STRATEGY | $20K | Supply chain modernization, Medical surgical prime vendor reforms, Prosthetic and implant program reforms. |
| 2025-01-20 | BSX | BOSTON SCIENTIFIC (OFFICE-BASED FACILITY ASSN OBFA) (FKA USPA) | LIBERTY PARTNERS GROUP, LLC | $0 | Medicare Physician Fee Schedule; Medicare Physician Fee Schedule reform; H.R.10136 - Promoting Fairness for Medicare Providers Act of 2024. |